Optimal targeting of HER2-PI3K signaling in breast cancer: Mechanistic insights and clinical implications

Brent N. Rexer; Carlos L. Arteaga

doi:10.1158/0008-5472.CAN-13-0687

Optimal targeting of HER2-PI3K signaling in breast cancer: Mechanistic insights and clinical implications

Brent N. Rexer, Carlos L. Arteaga

Research output: Contribution to journal › Review article › peer-review

48 Scopus citations

Abstract

The combination of a PI3K inhibitor with trastuzumab has been shown to be effective at overcoming trastuzumab resistance in models of HER2+ breast cancer by inhibiting HER2-PI3K-FOXO-survivin signaling. In this review the potential clinical implications of these findings are discussed.

Original language	English (US)
Pages (from-to)	3817-3820
Number of pages	4
Journal	Cancer research
Volume	73
Issue number	13
DOIs	https://doi.org/10.1158/0008-5472.CAN-13-0687
State	Published - Jul 1 2013

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/0008-5472.CAN-13-0687

Cite this

@article{970806a8238e457e8b024a45384725a9,

title = "Optimal targeting of HER2-PI3K signaling in breast cancer: Mechanistic insights and clinical implications",

abstract = "The combination of a PI3K inhibitor with trastuzumab has been shown to be effective at overcoming trastuzumab resistance in models of HER2+ breast cancer by inhibiting HER2-PI3K-FOXO-survivin signaling. In this review the potential clinical implications of these findings are discussed.",

author = "Rexer, {Brent N.} and Arteaga, {Carlos L.}",

year = "2013",

month = jul,

day = "1",

doi = "10.1158/0008-5472.CAN-13-0687",

language = "English (US)",

volume = "73",

pages = "3817--3820",

journal = "Cancer research",

issn = "0008-5472",

publisher = "American Association for Cancer Research Inc.",

number = "13",

}

TY - JOUR

T1 - Optimal targeting of HER2-PI3K signaling in breast cancer

T2 - Mechanistic insights and clinical implications

AU - Rexer, Brent N.

AU - Arteaga, Carlos L.

PY - 2013/7/1

Y1 - 2013/7/1

N2 - The combination of a PI3K inhibitor with trastuzumab has been shown to be effective at overcoming trastuzumab resistance in models of HER2+ breast cancer by inhibiting HER2-PI3K-FOXO-survivin signaling. In this review the potential clinical implications of these findings are discussed.

AB - The combination of a PI3K inhibitor with trastuzumab has been shown to be effective at overcoming trastuzumab resistance in models of HER2+ breast cancer by inhibiting HER2-PI3K-FOXO-survivin signaling. In this review the potential clinical implications of these findings are discussed.

UR - http://www.scopus.com/inward/record.url?scp=84880065874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880065874&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-13-0687

DO - 10.1158/0008-5472.CAN-13-0687

M3 - Review article

C2 - 23794708

AN - SCOPUS:84880065874

SN - 0008-5472

VL - 73

SP - 3817

EP - 3820

JO - Cancer research

JF - Cancer research

IS - 13

ER -

Optimal targeting of HER2-PI3K signaling in breast cancer: Mechanistic insights and clinical implications

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this